Ligand Pharma CEO Andrew Reardon Buys & Sells Shares Amid Strong Market Upswing
Ligand Pharmaceuticals’ CEO Andrew Reardon’s recent equity trades reveal strong insider confidence, highlighting the company’s growth in hormone‑targeted biotech.
3 minutes to read